Vifor Pharma AG VIF.N-CH:Swiss Exchange

*Data is delayed | CHF
Last | 5:30 PM CEST
127.00quote price arrow up+0.25 (+0.20%)
Volume
126,579
52 week range
99.68 - 140.55

...

Loading . . .
  • Open127.25
  • Day High127.75
  • Day Low125.65
  • Prev Close126.75
  • 52 Week High140.55
  • 52 Week High Date09/21/20
  • 52 Week Low99.68
  • 52 Week Low Date10/29/20

Key Stats

  • Market Cap9,053.28M
  • Shares Out64.86M
  • 10 Day Average Volume157,769.91
  • Dividend2.00
  • Dividend Yield1.57%
  • Beta-
  • YTD % Change-8.63

KEY STATS

  • Open127.25
  • Day High127.75
  • Day Low125.65
  • Prev Close126.75
  • 52 Week High140.55
  • 52 Week High Date09/21/20
  • 52 Week Low99.68
  • 52 Week Low Date10/29/20
  • Market Cap9,053.28M
  • Shares Out64.86M
  • 10 Day Average Volume157,769.91
  • Dividend2.00
  • Dividend Yield1.57%
  • Beta-
  • YTD % Change-8.63

RATIOS/PROFITABILITY

  • EPS (TTM)5.52
  • P/E (TTM)23.01
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Vifor Pharma AG

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Vifor Pharma AG, formerly known as Galenica AG, is a Switzerland-based company engaged in the healthcare market. The Company operates through a single pharmaceutical segment. It develops, manufactures and markets pharmaceutical products, specializing in therapies for iron deficiency, nephrology and cardio-renal diseases. The Company's portfolio of iron deficiency treatments includes intravenous products, Ferinject and Venofer, and oral product, Maltofer, among others. Its...
Jacques Theurillat
Non-Executive Chairman
Stefan Schulze
Chief Executive Officer
Colin Bond
Chief Financial Officer
Gregory Oakes
Executive Vice President
Address
Rechenstrasse 37
St. Gallen
9014
Switzerland